Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer

QR Code

Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer

ObjectiveThis study aims to evaluate the cost-effectiveness of using cadonilimab plus chemotherapy compared to chemotherapy in HER-2-negative advanced gastric cancer from the perspective of the Chinese healthcare system.MethodsA cost-effectiveness analysis was conducted utilizing a partitioned survi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Longfeng Zhang, Qingsheng Yang, Zhiwei Zheng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Public Health
Subjects:	advanced gastric cancer cadonilimab chemotherapy cost-effectiveness analysis HER-2-negative
Online Access:	https://www.frontiersin.org/articles/10.3389/fpubh.2025.1644176/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of cadonilimab plus bevacizumab and chemotherapy for persistent, recurrent, or metastatic cervical cancer
by: Kaixuan Wang, et al.
Published: (2025-06-01)

Cadonilimab in combination with chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis
by: Zuojuan Xiang, et al.
Published: (2025-07-01)

Case Report: Cadonilimab plus anlotinib with radiotherapy for lung adenocarcinoma with pancreatic metastasis in later-line therapy
by: Jianquan Yang, et al.
Published: (2025-07-01)

Clinical progress of cadonilimab in the treatment of malignant tumor
by: ZHANG Xiaoqing, et al.
Published: (2025-06-01)

HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN GASTRIC CANCER (GC) (RESULTS OF THE MULTICENTER CLINICAL TRIAL)
by: H. C. Chung, et al.
Published: (2017-02-01)

Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases
by: Hai-Zhen Yi, et al.
Published: (2025-07-01)

Cadonilimab combined with trastuzumab and chemotherapy for HER2-positive gastric cancer with bone marrow metastasis and DIC: a case report and literature review
by: Meijing Chen, et al.
Published: (2025-06-01)

THE ROLE OF ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED GASTRIC CANCER
by: A. A. Bobryshev, et al.
Published: (2021-03-01)

The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow’s oncologists
by: L. G. Zhukova, et al.
Published: (2020-06-01)

Successful subtotal gastrectomy and hepatectomy for HER2-positive gastric cancer with liver metastasis after trastuzumab-based chemotherapy: a case report
by: Yuki Hirase, et al.
Published: (2024-03-01)

Programmed death‐ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2‐negative status
by: Lei Wang, et al.
Published: (2018-06-01)

Helicobacter pylori-negative Gastric Cancer
by: Jin Seok Jang
Published: (2017-09-01)

Long-term survival after multidisciplinary treatments for HER2-positive advanced gastric cancer with multiple liver and lung metastases
by: Satoshi Yoshioka, et al.
Published: (2023-08-01)

Targeting PGK1 as a Novel strategy to regulate the sensitivity of HER2 positive gastric cancer to lapatinib
by: Xiaochen Ni, et al.
Published: (2025-07-01)

EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCER
by: A. A. Paichadze, et al.
Published: (2020-03-01)

Combined Oxaliplatin with 5-Fluorouracil for Effective Chemotherapy Against Gastric Cancer in Animal Model
by: Ren J, et al.
Published: (2025-06-01)

Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IVB HER2-positive gastric cancer
by: Xuchen Zhang, et al.
Published: (2025-07-01)

Real-world data of cadonilimab in recurrent or metastatic cervical cancer in China: a multicentric study
by: Jian Chen, et al.
Published: (2025-07-01)

The impact of delayed adjuvant chemotherapy on survival in gastric cancer patients with and without preoperative chemotherapy
by: Masataka Shimonosono, et al.
Published: (2025-07-01)

Successful conversion surgery for gastric cancer with multiple liver metastases treated after S-1 plus cisplatin combination chemotherapy: a case report
by: Masashi Tsunematsu, et al.
Published: (2017-08-01)

OUR EXPERIENCE OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY FOR PATIENTS WITH ADVANCED GASTRIC CANCER
by: A. D. Kaprin, et al.
Published: (2016-01-01)

Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report
by: Hiromi Nagata, et al.
Published: (2020-01-01)

Androgen receptor expression in triple negative breast cancer: an Algerian population study
by: Amel Hedjem, et al.
Published: (2025-12-01)

Clinical and morphological aspects of neoadjuvant chemotherapy efficacy in patients with aggressive luminal HER2-negative breast cancer
by: D. A. Morozov, et al.
Published: (2022-01-01)

The influence of H. pylori infection in HER2-positive gastric cancer cell lines: insights from Wnt/β-catenin pathway
by: Valli De Re, et al.
Published: (2025-06-01)

HER2 Reactivity Pattern and Association with Various Tumor Factors in Breast Cancer Patients
by: Greeshma Ann George, et al.
Published: (2025-04-01)

Molecular markers as predictors of response to perioperative chemotherapy in locally advanced gastric cancer
by: K. A. Oganyan, et al.
Published: (2023-04-01)

Immunomorphological specifcity of HER2-low breast cancer
by: I. V. Mikhailov, et al.
Published: (2024-11-01)

Successful conversion surgery for stage IV gastric cancer with liver metastases after second-line chemotherapy with ramucirumab and paclitaxel: a case report
by: Kosuke Fukuda, et al.
Published: (2022-04-01)

Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy
by: Rumeysa Colak, et al.
Published: (2025-06-01)

Cost-effectiveness analysis of sugemalimab combined with chemotherapy as first-line treatment for advanced gastric cancer
by: Lian Tang, et al.
Published: (2025-07-01)

Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01)

Long-term survival achieved by repeated administration of ramucirumab after drug holidays due to proteinuria in recurrent gastric cancer
by: Naoyuki Uehata, et al.
Published: (2021-04-01)

Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial
by: Roberto A. Leon-Ferre, et al.
Published: (2025-06-01)

Comparison of Neoadjuvant Chemotherapy With FLOT and Modified DCF Regimens in Nonmetastatic Gastric Adenocarcinoma
by: Mehdi Pourghasemian, et al.
Published: (2025-06-01)

PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY COMBINED WITH SYSTEM CHEMOTHERAPY – A NEW APPROACH TO TREATMENT OF GASTRIC CANCER PATIENTS WITH PERITONAL CARCINOMATOSIS
by: V. M. Khomyakov, et al.
Published: (2020-09-01)

A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer
by: A. V. Avgustinovich, et al.
Published: (2024-03-01)

A case of advanced gastric cancer achieved a pathological complete response by chemotherapy
by: Kazuhiro Tada, et al.
Published: (2017-05-01)

PREVENTION AND MONITORING OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER
by: N. A. Kozyavin, et al.
Published: (2018-08-01)

PD-L1 expression predicts the efficacy of PD-1 blockade plus chemotherapy versus chemotherapy alone in treatment-naïve advanced or metastatic gastric cancer: a pooled analysis of reconstructed individual patient-level data from two randomized trials
by: Wei Zhou, et al.
Published: (2025-07-01)